A Practical Guide to Understanding and Treating Peripheral Artery Disease.
Maya R Chilbert1, Ashley E Woodruff1, Kelly C Rogers2
1Department of Pharmacy, University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo General Medical Center; and.
Peripheral arterial disease (PAD) is underdiagnosed and undertreated. Early screening and risk factor management, including blood pressure and lipid control, are crucial for better patient outcomes.
Area of Science:
- Cardiovascular Medicine
- Vascular Surgery
Background:
- Peripheral arterial disease (PAD) is a significant cause of atherosclerotic morbidity, often overlooked compared to coronary heart disease and stroke.
- Underdiagnosis and undertreatment of PAD limit patient access to essential therapies and risk factor modification.
- Key risk factors for PAD include diabetes and cigarette smoking, necessitating targeted interventions.
Purpose of the Study:
- To provide a comprehensive overview of Peripheral Arterial Disease (PAD).
- To summarize current clinical trial evidence and guideline recommendations for PAD screening and treatment.
- To enhance healthcare provider awareness of PAD for improved patient care.
Main Methods:
- This narrative review synthesizes existing literature on PAD screening and treatment.
- Guideline recommendations and clinical trial data are summarized.
- Focus is placed on risk factor management and individualized treatment strategies.
Main Results:
- Effective management of risk factors like diabetes and smoking improves PAD outcomes.
- Blood pressure and lipid control are essential for mitigating PAD symptoms and manifestations.
- Individualized antithrombotic medication use is recommended based on patient-specific factors.
Conclusions:
- Healthcare providers should integrate PAD screening into routine care for at-risk populations.
- Early diagnosis and guideline-directed therapy initiation are critical for reducing adverse CV and limb events.
- Enhanced provider awareness and adherence to treatment guidelines can positively impact patient care and outcomes.
More Related Videos
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Pulse Assessment Sites
Assessment of the Cardiovascular System III: Palpation
Jugular Venous Pressure (JVP) Measurement
Position the patient at a thirty- to forty-five-degree angle or in a semi-fowler's position. Look for the highest point of pulsation in the internal jugular vein and measure the vertical distance to the angle of Loius or sternal angle. A normal JVP is 3-4 cm above...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pre-Procedural Guidelines for Assessing Blood Pressure


